Royalty Report: Drugs, Disease, Therapeutic – Collection: 63806


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 63806

License Grant
The Company entered into a collaboration and license agreement to license, research, develop and commercialize pharmaceutical compounds from the Company’s 3GA technology for the treatment of selected targets in renal disease.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 5425

License Grant
The Licensor and the Licensee desire to enter into a collaborative relationship to conduct research to identify novel targets for drug discovery, as generally described in the Research Plan, with Licensee developing and commercializing any compounds resulting therefrom.

IPSCIO Record ID: 253901

License Grant
The Parties entered a joint research and development effort to discover and/or design Nonsteroidal Compounds which act through the progesterone receptor and to develop pharmaceutical products from such compounds.  Under the terms of the collaboration, the Licensee of the Netherlands was granted exclusive worldwide rights to manufacture and sell any products resulting from the collaboration.

Licensor grants the Licensee of the Netherlands an exclusive, worldwide license, with the right to sublicense, which license shall be exclusive even as to Licensor, under Licensors Patent Rights and Collaboration Technology owned or Controlled by or licensed to Licensor, including Licensors rights in any jointly owned Patent Rights to the extent necessary, to develop, make, have made, use, manufacture, have manufactured, import, promote, offer for sale, sell, distribute, market and commercialize, with the right to sublicense, any Products in the Field.

License Property
Licensor has developed certain expertise and acquired certain proprietary rights relating to the discovery and development of pharmaceutical products for the treatment and prevention of diseases, which products act through the progesterone receptor.

The Collaboration Compound shall mean a Nonsteroidal Compound which is first identified, first confirmed, first discovered, or first synthesized and identified by either Party as mediating the activity of the Designated Target during the Research Term and those Nonsteroidal Compounds under development by Licensee as of the Commencement Date that mediate the activity of the Designated Target.

The Designated Target  shall mean the progesterone receptor, including all isoforms and variants thereof.

Product shall mean a pharmaceutical product which has as one of its active ingredients a Collaboration Lead Compound that has been approved by the applicable Regulatory Agency for marketing in a country for treatment, palliation or prevention of disease in the Field.

Field of Use
The collaboration is to focus on small molecule compounds with potential effects for the treatment and prevention of gynecological diseases mediated through the progesterone receptor.

The field shall mean the discovery, characterization, design and development of Nonsteroidal Compounds for the treatment or prevention of diseases whose beneficial effects are mediated through the Designated Target.

The research and development collaboration focus on small molecule compounds with potential effects for the treatment and prevention of gynecological diseases mediated through the progesterone receptor.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.